Belgium· BE-AMP-SAM553617-00

Nucala 100 mg

A mepolizumab product containing mepolizumab, registered in Belgium by GlaxoSmithKline Trading Services. The same ATC class is registered in 13 of our 19 countries.

ATC R03DX09

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedNucala 100 mgATCR03DX09REGISTER NO.BE-AMP-SAM553617-00PACKS LISTED6CHECKEDSeptember 26, 2026

Where it is registered

Mepolizumab is registered in 13 of 19 countries.

Countries holding a registration under ATC R03DX09 (mepolizumab), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 8 of them publish a price we can compare per daily dose

Mepolizumab · ATC R03DX09

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Mepolizumab
Manufacturer
GlaxoSmithKline Trading Services
Country
Belgium (BE)
ATC code
R03DX09
ATC class
Mepolizumab
Defined daily dose
3.6 mg, P
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 6

4 priced
  • be_apb
    4254934
    EUR 3310.92
  • be_apb
    4156832
    EUR 1110.95
  • be_apb
    7728231
  • be_apb
    4106902
    EUR 956.96
  • be_apb
    4106910
    EUR 2848.92
  • be_apb
    7727068

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d0048210-ddfd-45aa-9fe4-636c46812c8b
GET /v1/drugs/d0048210-ddfd-45aa-9fe4-636c46812c8b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for injection in pre-filled pen",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Nucala 100 mg",
  "name_fr": "Nucala 100 mg",
  "name_nl": "Nucala 100 mg",
  "amp_code": "SAM553617-00",
  "strengths": [
    "100.0000",
    "100.0000"
  ],
  "pack_count": 5,
  "substances": [
    "Mepolizumab",
    "Disodium Edetate",
    "Disodium Hydrogen Phosphate Heptahydrate",
    "Sucrose",
    "Polysorbate 80"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Mepolizumab",
  "authorisation_numbers": [
    "EU/1/15/1043/003",
    "EU/1/15/1043/004",
    "EU/1/15/1043/007"
  ]
}

See everything about mepolizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.